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To be perfectly frank, there is no proper therapy for 
Sjögren’s syndrome. Of course, there are therapies to 
treat the symptoms, but none that treats the underlying 
patholophysiology. Th   ere may be an obvious underlying 
reason that we cannot target the immunological or 
biological cause of Sjögren’s syndrome. Namely, we as a 
community (that is, the research and clinical community 
interested in the disease) do not really understand the 
(presumed) immunological events leading to, advancing, 
and perpetuating this disease. Th   is predicament begs the 
question of the basic assumption of biomedical research, 
especially translational research in which a human 
condition is under study. Th   at is, a fuller understanding 
of patho  physiological mechanisms will naturally lead to 
therapies based on that understanding.
In the previous issue of Arthritis Research & Th  erapy, 
Kang and colleagues [1] studied interleukin-21 (IL-21) in 
Sjögren’s syndrome. Will determining that this cytokine 
is involved in Sjögren’s syndrome open new therapeutic 
opportunities? Th  is has certainly occurred in other 
illnesses within the domain of rheuma  tology, both in 
common and in uncommon illnesses. When I was an 
internal medicine resident, not that long ago, the duties 
of the rheumatology clinic consisted mostly of checking 
urine analysis results and complete blood counts to 
determine whether patients with rheumatoid arthritis 
could receive a gold shot that day. A lot has changed since 
then – mostly because research determined that tumor 
necrosis factor-alpha (TNFα) is involved in the 
pathogenesis of rheuma  toid arthritis. Th  is led to the 
development of speciﬁ   c anti-TNF therapies, which 
basically changed the nature and natural history of the 
disease [2]. Pascual and colleagues [3] discovered that 
IL-1 is overexpressed in children with systemic-onset 
juvenile idiopathic arthritis. Th  is know  ledge led to a 
clinical trial of anti-IL-1 therapy in this illness, which was 
largely unresponsive to other, un  directed therapies [4]. 
Dissecting genetic risk factors has led to therapy. For 
example, autosomal dominant periodic fever syndromes 
were determined to be caused by mutations in the TNFα 
receptor, and anti-TNF therapy works well in this disease 
[5], which is now known as TNF receptor-associated 
periodic syndrome (TRAPS). Common population 
variants of the IL-23 gene are associated with psoriasis, a 
genetically complex disease [6]. Th  ese genetic data, in 
part, gave rise to a clinical trial of an anti-IL-23 
monoclonal antibody, which was found to be eﬀ  ective, in 
psoriasis [7]. Development of anti-interferon therapy is 
being undertaken with systemic lupus erythematosus as 
the target illness.
Th   e known functions of IL-21 ﬁ  t well with the ﬁ  ndings 
in patients with Sjögren’s syndrome. Th  e disease is 
characterized by lymphocytic inﬁ  ltrates in the salivary 
and lacrimal glands that contain both B and T cells that 
in many patients demonstrate ectopic germinal center 
formation. Kang and colleagues found that the degree of 
lymphocytic inﬁ  ltration was correlated with IL-21 levels. 
Proliferation of both naïve and memory CD8+ T cells as 
well as activation, proliferation, and survival of CD4+
T cells are supported by IL-21. B cells and CD4+ T cells 
are prominent in Sjögren’s inﬁ  ltrates. Furthermore, Kang 
and colleagues found expression of IL-21 in the inﬁ  l  trat-
ing cells. Th  ere are, of course, high levels of auto  anti-
bodies in the form of concentrations (in milligram per 
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symptomatic. A lack of true understanding of the 
underlying immunological pathology of the disease 
prevents directed therapy. Interleukin-21 (IL-21) is 
elevated in the serum of patients with this disease and 
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this disease.
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© 2011 BioMed Central Ltddeciliter) of anti-Ro (or SSA) and anti-La (or SSB), along 
with consequent hypergamma  globuline  mia, especially 
IgG1. Th   e data are clear that B cells are hyperactivated in 
patients with Sjögren’s syndrome. IL-21 promotes the 
proliferation of B cells, resulting in diﬀ  er  entiation into 
plasma cells, which produce immuno  globulin, especially 
IgG1.
IL-21 is involved in the diﬀ  erentiation of T helper 17 
(Th   17) cells in that IL-21 acts to facilitate IL-23-induced 
expansion of these cells. As noted above, an IL-23 mono-
clonal antibody is available clinically, but the involvement 
of Th   17 cells in the pathogenesis of Sjögren’s syndrome is 
unknown. If Th  17 cells are, in fact, players in Sjögren’s 
syndrome, then perhaps the available anti-IL-23 mono-
clonal antibodies would be beneﬁ  cial in the disease. Th  is, 
of course, remains to be determined.
Certainly, the ﬁ  ndings reported by Kang and colleagues 
[1] as well as others in regard to IL-21 in Sjögren’s syn-
drome [8] and other inﬂ  ammatory rheumatic illnesses 
[9,10] suggest that therapy directed at IL-21 may be 
useful in human autoimmune disease. Th  ese ﬁ  ndings 
need to be conﬁ   rmed and advanced but perhaps will 
underpin the development of therapy directed at the 
underlying pathophysiology of Sjögren’s syndrome.
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